+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Artificial Intelligence In Cardiology Market Size, Share & Industry Analysis Report By Component, By Application,. By Medical Condition, By Country and Growth Forecast, 2025 - 2032

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 6107896
The Latin America, Middle East and Africa Artificial Intelligence In Cardiology Market is expected to witness market growth of 33.8% CAGR during the forecast period (2025-2032).

The Brazil market dominated the LAMEA Artificial Intelligence In Cardiology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $279.4 million by 2032. The Argentina market is showcasing a CAGR of 34.8% during 2025-2032. Additionally, the UAE market would register a CAGR of 32.4% during 2025-2032.



AI’s uses in cardiology are diverse, encompassing diagnostics, treatment planning, patient monitoring, and research. In diagnostics, AI enhances the accuracy of detecting conditions like atrial fibrillation (AF), heart failure, and CAD. For example, Koninklijke Philips N.V.’s ePatch, deployed across Spain in May 2024, utilizes the AI-driven Cardiologs analytics platform to detect heart arrhythmias such as AF, improving diagnostic precision through continuous monitoring.

In treatment planning, AI supports clinicians by analyzing patient data to recommend personalized interventions. The Viz Cardio Suite, launched by Viz.ai in November 2022, integrates AI to streamline cardiovascular care by combining data to produce clinical insights, accelerating communication, and ensuring patients receive timely downstream treatments. AI also plays a pivotal role in drug discovery by analyzing biomolecular networks to identify novel therapeutic targets, reducing the time and cost of developing new cardiovascular drugs.

The LAMEA region, encompassing Latin America, the Middle East, and Africa, is increasingly becoming a focal point for the application of Artificial Intelligence (AI) in cardiology. While historically challenged by limited healthcare infrastructure and disparities in medical access, the region is now witnessing a transformative shift driven by digital health innovation and government-backed modernization initiatives. Cardiovascular diseases remain among the leading causes of mortality in LAMEA, placing substantial pressure on healthcare systems to improve diagnostic accuracy, reduce treatment delays, and manage chronic conditions more efficiently.

AI technologies, particularly in cardiology, are being embraced as critical tools to address these challenges. AI-driven solutions offer capabilities such as real-time diagnostics, predictive analytics, and remote monitoring, enabling healthcare providers to detect cardiovascular issues at earlier stages and personalize treatment strategies. The demand for such technologies has grown in tandem with the region’s rising mobile connectivity, increasing investments in health tech startups, and the emergence of digital-first healthcare ecosystems.

Key influencing factors include government initiatives to modernize healthcare systems, the need for cost-effective diagnostic tools, and the growing awareness of AI's potential in improving patient outcomes. Market trends reveal a focus on integrating AI into telemedicine platforms and developing AI-powered diagnostic imaging solutions. The competitive landscape comprises international companies like GE Healthcare and Philips, as well as regional startups developing AI applications tailored to local healthcare needs. Therefore, the LAMEA region stands at a pivotal juncture in the evolution of AI in cardiology. With a mix of structural challenges and emerging opportunities, the region is poised to benefit significantly from scalable, AI-enabled cardiovascular care solutions that promise improved patient outcomes and healthcare efficiency.

List of Key Companies Profiled

  • IDOVEN S.L.
  • Ultromics Ltd.
  • CardiAI.Inc.
  • Tempus AI, Inc.
  • Koninklijke Philips N.V.
  • Cleerly, Inc.
  • Vista AI, Inc.
  • Viz.ai, Inc.
  • RSIP Vision Ltd.
  • GE HealthCare Technologies, Inc.

Market Report Segmentation

By Component

  • Hardware
  • Software
  • Services

By Application

  • Diagnosis
  • Prediction
  • Drug Discovery
  • Other Application

By Medical Condition

  • Ischemic Heart Disease /CAD
  • Cardiac Arrhythmias
  • Heart Failure
  • Other Medical Condition

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Artificial Intelligence In Cardiology Market, by Component
1.4.2 LAMEA Artificial Intelligence In Cardiology Market, by Application
1.4.3 LAMEA Artificial Intelligence In Cardiology Market, by Medical Condition
1.4.4 LAMEA Artificial Intelligence In Cardiology Market, by Country
1.5 Methodology for the Research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis - Global
4.1 Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Market Share Analysis, 2024
4.4 Top Winning Strategies
4.4.1 Key Leading Strategies: Percentage Distribution (2021-2025)
4.4.2 Key Strategic Move: (Product Launches and Product Expansions : 2021, Nov - 2025, Apr) Leading Players
4.5 Porter Five Forces Analysis
Chapter 5. Value Chain Analysis of Artificial Intelligence In Cardiology Market
5.1 Research & Development (R&D)
5.2 Data Acquisition & Management
5.3 Model Development & Training
5.4 Regulatory Approval & Certification
5.5 Product Integration & Deployment
5.6 Marketing & Sales
5.7 After-Sales Support & Feedback Loop
Chapter 6. Key Customer Criteria - Artificial Intelligence In Cardiology Market
6.1 Diagnostic Accuracy
6.2 Regulatory Compliance
6.3 Data Privacy and Security
6.4 Integration with Existing Healthcare Systems
6.5 Clinical Validation and Peer-Reviewed Evidence
6.6 Ease of Use and Interface Design
6.7 Real-Time Processing and Speed
6.8 Cost-Effectiveness and Return on Investment (ROI)
6.9 Continuous Learning and Model Updates
6.10. Vendor Support and Training Services
Chapter 7. LAMEA Artificial Intelligence In Cardiology Market by Component
7.1 LAMEA Hardware Market by Country
7.2 LAMEA Software Market by Country
7.3 LAMEA Services Market by Country
Chapter 8. LAMEA Artificial Intelligence In Cardiology Market by Application
8.1 LAMEA Diagnosis Market by Country
8.2 LAMEA Prediction Market by Country
8.3 LAMEA Drug Discovery Market by Country
8.4 LAMEA Other Application Market by Country
Chapter 9. LAMEA Artificial Intelligence In Cardiology Market by Medical Condition
9.1 LAMEA Ischemic Heart Disease /CAD Market by Country
9.2 LAMEA Cardiac Arrhythmias Market by Country
9.3 LAMEA Heart Failure Market by Country
9.4 LAMEA Other Medical Condition Market by Country
Chapter 10. LAMEA Artificial Intelligence In Cardiology Market by Country
10.1 Brazil Artificial Intelligence In Cardiology Market
10.1.1 Brazil Artificial Intelligence In Cardiology Market by Component
10.1.2 Brazil Artificial Intelligence In Cardiology Market by Application
10.1.3 Brazil Artificial Intelligence In Cardiology Market by Medical Condition
10.2 Argentina Artificial Intelligence In Cardiology Market
10.2.1 Argentina Artificial Intelligence In Cardiology Market by Component
10.2.2 Argentina Artificial Intelligence In Cardiology Market by Application
10.2.3 Argentina Artificial Intelligence In Cardiology Market by Medical Condition
10.3 UAE Artificial Intelligence In Cardiology Market
10.3.1 UAE Artificial Intelligence In Cardiology Market by Component
10.3.2 UAE Artificial Intelligence In Cardiology Market by Application
10.3.3 UAE Artificial Intelligence In Cardiology Market by Medical Condition
10.4 Saudi Arabia Artificial Intelligence In Cardiology Market
10.4.1 Saudi Arabia Artificial Intelligence In Cardiology Market by Component
10.4.2 Saudi Arabia Artificial Intelligence In Cardiology Market by Application
10.4.3 Saudi Arabia Artificial Intelligence In Cardiology Market by Medical Condition
10.5 South Africa Artificial Intelligence In Cardiology Market
10.5.1 South Africa Artificial Intelligence In Cardiology Market by Component
10.5.2 South Africa Artificial Intelligence In Cardiology Market by Application
10.5.3 South Africa Artificial Intelligence In Cardiology Market by Medical Condition
10.6 Nigeria Artificial Intelligence In Cardiology Market
10.6.1 Nigeria Artificial Intelligence In Cardiology Market by Component
10.6.2 Nigeria Artificial Intelligence In Cardiology Market by Application
10.6.3 Nigeria Artificial Intelligence In Cardiology Market by Medical Condition
10.7 Rest of LAMEA Artificial Intelligence In Cardiology Market
10.7.1 Rest of LAMEA Artificial Intelligence In Cardiology Market by Component
10.7.2 Rest of LAMEA Artificial Intelligence In Cardiology Market by Application
10.7.3 Rest of LAMEA Artificial Intelligence In Cardiology Market by Medical Condition
Chapter 11. Company Profiles
11.1 IDOVEN S.L.
11.1.1 Company Overview
11.2 Ultromics Ltd.
11.2.1 Company Overview
11.2.2 Recent Strategies and Developments
11.2.2.1 Partnerships, Collaborations, and Agreements
11.2.2.2 Product Launches and Product Expansions
11.3 CardiAI Inc.
11.3.1 Company Overview
11.4 Tempus AI, Inc.
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Research & Development Expenses
11.4.4 Recent Strategies and Developments
11.4.4.1 Product Launches and Product Expansions
11.4.4.2 Acquisition and Mergers
11.4.5 SWOT Analysis
11.5 Koninklijke Philips N.V.
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Segmental and Regional Analysis
11.5.4 Research & Development Expense
11.5.5 Recent Strategies and Developments
11.5.5.1 Partnerships, Collaborations, and Agreements
11.5.5.2 Product Launches and Product Expansions
11.5.5.3 Acquisition and Mergers
11.5.6 SWOT Analysis
11.6 Cleerly, Inc.
11.6.1 Company Overview
11.6.2 Recent Strategies and Developments
11.6.2.1 Partnerships, Collaborations, and Agreements
11.7 Vista AI, Inc.
11.7.1 Company Overview
11.8 Viz.ai, Inc.
11.8.1 Company Overview
11.8.2 Recent Strategies and Developments
11.8.2.1 Partnerships, Collaborations, and Agreements
11.8.2.2 Product Launches and Product Expansions
11.9 RSIP Vision Ltd.
11.9.1 Company Overview
11.10. GE HealthCare Technologies, Inc.
11.10.1 Company Overview
11.10.2 Financial Analysis
11.10.3 Segmental and Regional Analysis
11.10.4 Research & Development Expenses
11.10.5 Recent Strategies and Developments
11.10.5.1 Product Launches and Product Expansions
11.10.6 SWOT Analysis

Companies Mentioned

  • IDOVEN S.L.
  • Ultromics Ltd.
  • CardiAI.Inc.
  • Tempus AI, Inc.
  • Koninklijke Philips N.V.
  • Cleerly, Inc.
  • Vista AI, Inc.
  • Viz.ai, Inc.
  • RSIP Vision Ltd.
  • GE HealthCare Technologies, Inc.